NMN

A recent clip from the episode featuring Dr. Peter Attia discusses NMN (Nicotinamide Mononucleotide), its potential benefits, and the skepticism surrounding its efficacy as a supplement. Here are some key points highlighted in that discussion:

• Market Status: Some major companies have pulled NMN from the market, but smaller companies continue to sell it online. The discussion did not strongly argue for the need to take NMN supplements at this time 1.

• Potential Benefits: Dr. Attia mentioned that the strongest argument for taking NMN might be its potential to reduce risks associated with basal cell and squamous cell carcinoma, though this requires further validation 1.

• Safety Concerns: Both Andrew Huberman and Dr. Attia noted that while NMN and its variant NR (Nicotinamide Riboside) might be safe, there are concerns that NR could potentially increase cancer risk, though studies supporting this are not considered robust 1.

• Lack of Rigorous Research: The lack of well-done studies in this area raises questions about NMN's claims, especially regarding its connection to lifespan extension. Dr. Attia emphasized that much of the current research does not meet the rigor expected in pharmacological studies 1.

For more details, you can listen to the entire discussion in the episode titled "Dr. Peter Attia: Supplements for Longevity & Their Efficacy" on the Huberman Lab.